Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05714553 |
TitleNUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase
Phase 1, Phase 2
|
Date Added 2023-02-06 |
Location
United Kingdom
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Docetaxel, Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab |
Tags
MSI-H/ MMRd
|
| NCT ID NCT04332653 |
TitleNT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2020-04-03 |
Location
Florida, United States
Michigan, United States Missouri, United States North Carolina, United States Pennsylvania, United States Tennessee, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
NT-I7, Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT04041310 |
TitleNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2019-08-01 |
Location
California, United States
Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States Belgium Canada Italy Spain United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05213195 |
TitleNKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2022-01-28 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
NKG2D CAR-NK |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04575922 |
TitleNivolumab+Ipilimumab+RT in MSS mCRC | Phase
Phase 2
|
Date Added 2020-10-05 |
Location
Massachusetts, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Ipilimumab, Nivolumab |
Tags
MSS/ MMRp
|
| NCT ID NCT03104439 |
TitleNivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | Phase
Phase 2
|
Date Added 2017-04-07 |
Location
Massachusetts, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Ipilimumab, Nivolumab, Opdivo, Yervoy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03983993 |
TitleNiraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2019-06-12 |
Location
Georgia, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Niraparib, panitumumab, Vectibix, Zejula |
Tags
MSS/ MMRp
|
| NCT ID NCT04940546 |
TitleNeoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients | Phase
Phase 1, Phase 2
|
Date Added 2021-06-25 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bevacizumab, capecitabine, oxaliplatin, Sintilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT05798533 |
TitleNeo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | Phase
Phase 1
|
Date Added 2023-04-04 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Cyclophosphamide, Fludarabine, Interleukin-2 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05783089 |
TitleMSLN-targeted CAR-T Cells in Solid Tumors. | Phase
Phase 1
|
Date Added 2023-03-24 |
Location |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
